Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers with adenocarcinoma being the most common subtype. Patients with stage IV NSCLC typically have poor prognosis. In these patients, identification of actionable genomic alterations allows for the selection of targeted th...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Angel Kwan Qi Wong, Saqib Raza Khan, Danial Khan Hadi, Daniel Breadner, Mark David Vincent
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2026-01-01
Serija:	Current Oncology
Teme:	non-small cell lung cancer EGFR mutation uncommon mutation osimertinib OCELOT clinical trial
Online dostop:	https://www.mdpi.com/1718-7729/33/1/55
Oznake:	Označite Brez oznak, prvi označite!